Literature DB >> 7999792

Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells.

K Staron1, B Kowalska-Loth, J Zabek, R M Czerwinski, K Nieznanski, I Szumiel.   

Abstract

Two sublines of LY murine lymphoma, differing in sensitivity to CPT, served as source of topoisomerase I in order to compare the enzyme's properties. The activity of topoisomerase I isolated from LY-S cells of reduced sensitivity to CPT increased about 2-times more upon phosphorylation with casein kinase but was inhibited to a lesser extent upon dephosphorylation with alkaline phosphatase than the enzyme from the CPT-sensitive LY-R cells. The in vitro phosphorylation of LY-S enzyme restored its sensitivity to CPT. The in vitro incorporation of 32P into topoisomerase protein was about 1.7-times higher in LY-S than in LY-R enzyme. A reversed incorporation ratio was observed upon metabolic labelling. The level of topoisomerase I protein, determined by Western blot analysis using scleroderma anti-topoisomerase I antibodies, was about 1.5-times higher in LY-S than in LY-R cells. The level of topoisomerase I mRNA was similar in both sublines. These results indicate that the reduced sensitivity of LY-S cells to CPT is based on the lowered phosphorylation of topoisomerase I protein but does not depend on the expression of topoisomerase I gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7999792     DOI: 10.1016/0167-4781(94)00175-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.

Authors:  Keya Bandyopadhyay; Ruth A Gjerset
Journal:  Biochemistry       Date:  2011-01-12       Impact factor: 3.162

2.  Phosphorylation of serine residues in the N-terminal domains of eukaryotic type I topoisomerases.

Authors:  K Staron; D S Samuels
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

3.  Contribution of topoisomerase I to conversion of single-strand into double-strand DNA breaks.

Authors:  B Kowalska-Loth; I Bubko; B Komorowska; I Szumiel; K Staron
Journal:  Mol Biol Rep       Date:  1998-01       Impact factor: 2.316

4.  Modulation of the effect of camptothecin in x-irradiated L5178Y-R and L5178Y-S cells by benzamide.

Authors:  I Gradzka; T Iwaneńko; M Kruszewski; I Szumiel; M Kapiszewska; C S Lange; G Afanasjev
Journal:  Radiat Environ Biophys       Date:  1996-08       Impact factor: 1.925

5.  Characterization of BTBD1 and BTBD2, two similar BTB-domain-containing Kelch-like proteins that interact with Topoisomerase I.

Authors:  Lixin Xu; Lihong Yang; Keiko Hashimoto; Melvin Anderson; Glenda Kohlhagen; Yves Pommier; Peter D'Arpa
Journal:  BMC Genomics       Date:  2002-01-07       Impact factor: 3.969

6.  Different Camptothecin Sensitivities in Subpopulations of Colon Cancer Cells Correlate with Expression of Different Phospho-Isoforms of Topoisomerase I with Different Activities.

Authors:  Cinzia Tesauro; Josephine Geertsen Keller; Irina Gromova; Pavel Gromov; Rikke Frohlich; Jens Uldum Erlandsen; Anni H Andersen; Magnus Stougaard; Birgitta R Knudsen
Journal:  Cancers (Basel)       Date:  2020-05-14       Impact factor: 6.639

7.  CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.

Authors:  Keya Bandyopadhyay; Pingchuan Li; Ruth A Gjerset
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

8.  Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I.

Authors:  Amit Roy; Cinzia Tesauro; Rikke Frøhlich; Marianne S Hede; Maria J Nielsen; Eigil Kjeldsen; Bjarne Bonven; Magnus Stougaard; Irina Gromova; Birgitta R Knudsen
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.